STUDresearch · Non-peptide
ATX-304
Also known as
O-304 · O304 · OS-01 · ATX304 · ATX 304 · Amplifier Therapeutics ATX-304 · Cambrian ATX-304
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Non-peptide
Lots of talk
Systemic
Oral
Metabolic & longevity adjacents
Systemic oral small molecule.
What people say
ATX-304, also called O304, is an oral research small molecule discussed for AMPK-related metabolic goals. It is not MOTS-c, metformin or a GLP-1, and clinical research is not proof of gray-capsule performance.
Doses people talk about
These amounts describe separate accounts, not a progression. The preserved 5 mg SC comparison is MOTS-c, not ATX; metformin grams are not interchangeable. Weekly milligrams remain unsettled.
How it may feel
Reports range from nothing or “expensive metformin” to warmth, more sweating and claimed weight loss over weeks. Exercise, diet and GLP/SLU co-use blur attribution; some describe overnight glucose-crash symptoms with MOTS-c.
Lower public log100 mg oral
A standalone first-look amount and a daily ATX-with-tirz account; one user described limited extra benefit. The 100 mg figure is ATX, not tirzepatide.
Daily cost-limited talk150 mg+ daily
The retained X band is framed around affordability. A separate checked oral log used 200–350 mg/day split in two for 8 weeks; it is not an efficacy threshold.
Half-life & effect duration
- Half-life in the body
- Community estimateAbout 4 days
- Felt duration people report
- During exercise · with SLUMore sweat in one account
- Continued useWeight-loss claims across an 8-week run; some report little benefit
Cycles people discuss
Daily, open-ended experiments and months-long use appear, often limited by cost or changing GLP doses. A once-weekly workaround is also reported, but neither a standard cycle nor weekly milligram chart is established.
Timing
Morning-with-the-stack is the reported habit, with some fasted-cardio timing. The old ~4-day half-life claim is unverified here; clinical steady state at day 14 does not validate daily versus weekly self-use.
Stacks
GLPs, GH and apitegromab appear in screenshots. Metformin, berberine and MOTS-c are sometimes alternatives and sometimes co-used; glucose-drop reports complicate the shared AMPK narrative.
Access talk
Two different ATXs: Amplifier / Cambrian trial tablets (not for sale) vs RUO “ATX-304 / O-304 / OS-01” research caps / powder (Elite Research-class shops named on X).
Labs people mention
Glucose / CGM is the stack-risk lab — especially + metformin, berberine, MOTS-c, or a GLP. Overnight crash logs are the 2026 watch.
Watch for
Dual AMPK overnight hypo talk when stacked with MOTS-c.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
The checked primary main text does not establish a numeric human half-life.
It describes a long plasma half-life and steady state after 14 days during a 28-day study. The existing ~4-day X claim is retained as unverified community attribution.
The main article's qualitative human wording and rodent observations are not a measured 4-day human estimate. No dosing interval is inferred from time to steady state.
- Steneberg et al. — O304 metabolic research and 28-day human trial (opens in a new tab)Original full article: Results AMPK dephosphorylation/PP2C experiments; human phase IIa and Discussion paragraphs describing long plasma half-life, steady state after 14 days and 21–28-day fasting-glucose outcomes.Relevant full main-text sections read directly from JCI Insight HTML after browser extraction timeouts. No supplemental human terminal-PK table reviewed; rodent and human results distinguished.
Felt duration people report
A reliable after-dose felt window is not established by the checked accounts.
Reports include more sweat during cardio with SLU co-use and an 8-week weight-loss account. A forum author timed it before fasted cardio but invoked unverified half-life reasoning.
No isolated duration/offset experiment; exercise, diet, product identity and co-use confound reports. Clinical 21–28-day glucose outcomes are not a subjective clock.
- ATX-304 — cardio sweat account with SLU co-use (opens in a new tab)Josh Large public opening post, December 2025: 200 mg/day, more sweat during cardio and SLU heat context.Actual public OP read. The listed 27 comments were inaccessible; search-result comments were not treated as reviewed evidence.
- BAM-15, SLU and ATX-304 — oral ATX course and timing follow-up (opens in a new tab)Visible posts 1–8: otisw #3 (August 24, 2026) oral 200–350 mg/day split twice for 8 weeks, 1.5 lb/week claim and estimated deficit; same author #8 (August 26, 2026), free-acid product before fasted cardio.Actual posts through #8 read; later pages not reviewed after redirect/extraction failures. Self-estimated calorie deficit, not measured energy expenditure; timing rationale is the user's belief.
What people say
- “I loved ATX” n=1s: Energy, training volume, “go harder without the crash” vs MOTS-c flops. anecdote
- Not a weekly pin: The job is daily (or weekly-strategy) swallow while the metabolic experiment is on. forum
- Drop-MOTS-c logs: 2026 X n=1s who ran MOTS-c (and sometimes SS-31) then switched to O-304 / ATX because the peptide “did nothing they could feel.” Attribution is still n=1. anecdote
- Fat-mass talk: Animal write-ups people paste: fat down, lean not wrecked the same way as a hard GLP. animal
- GLP combo hype: Mouse charts of ATX + sema dropping more weight, faster, then holding when sema is cut. X treats that as the recomp screenshot. animal
- Liver / lipids: Fatty-liver Phase 2 talk and cholesterol/steatosis papers in the same threads. trial
- Endurance lore: Exercise-capacity animal notes get copied into “zone-2 in a pill” posts. animal
- Clinic vs X: June 2026 Cambrian / Amplifier Phase 1b talk (obesity / prediabetes) — liver fat, visceral fat, triglycerides, adiponectin, resting metabolic rate — is what people paste next to 100–150 mg gray caps. Phase 2 (REWIRE) was still “planned.” Not a fat-loss label. trial
Doses people talk about
- 100 mg oral: Shows up as a first look. forum
- 150 mg+ daily: The “when money permits” band on X. forum
- Once-weekly experiments: Named after daily was annoying or sides showed. Exact weekly milligrams are not a settled chart. forum
- Not MOTS-c milligrams. Do not copy 5 mg SC onto this pill. forum
- Not metformin grams. Different molecule. forum
- Framing: Research-chem milligrams and n=1s — not a label, not a protocol. forum
How it may feel
- First days / acute impressions: Some report nothing; others describe warmth or fidgetiness, often attributing it to uncoupling. One public 200 mg/day account noted more sweat during cardio while also using SLU. The co-use and exercise context prevent an isolated ATX effect claim. forum
- Weeks 2–4 and longer logs: The “scale moved without eating less” camp contrasts with “expensive metformin.” One forum user later described 200–350 mg/day orally in two portions for 8 weeks, about 1.5 lb/week loss and a claimed 200–300 calorie deficit they attributed to ATX. This remains a self-account, not measured energy expenditure or a dose target. forum
- 100 mg n=1: One public log said 100 mg “wasn’t that much more beneficial.” anecdote
- 150 mg+ talk: Jake’s line is ATX is the better metformin pivot *when money permits 150 mg+ daily.* forum
- Weekly workaround: Nelly posted a once-weekly strategy “around the problem” after daily didn’t fit. forum
- Stopping: Older discussion describes no “peptide crash” and assumes weight/energy impressions fade like an oral drug. The inspected accounts do not establish a withdrawal pattern or a dependable time for effects to wear off. forum
- AMPK stack crash: 2026 X log of MOTS-c + O-304 bringing 4am blood-sugar-crash wake-ups. Dual AMPK is the named risk, not a studied combo. anecdote
Around the dose
- Clock: Morning oral AMPK talk — same neighborhood as MOTS-c / metformin comparisons. forum
- Training: Often stacked with a walk or session, not a night capsule. forum
- Vs MOTS-c clock: MOTS-c is a pin around training; ATX is a morning swallow. Do not copy 5 mg SC onto this pill. forum
- Metformin window: Jake-style 2026 talk keeps metformin later / away from the workout and puts ATX in the morning — personal timing lore. forum
- Glucose: If already on metformin, berberine, MOTS-c, or a GLP, 2026 crash logs are why people watch overnight CGM. forum
- After / movement context: Walks, training and activity recur in AMPK discussion; the old “swallow and sit” criticism is community framing, not proof that movement validates ATX or a required after-dose instruction. forum
Cycles people discuss
- Daily open-ended while the fat-loss or mito experiment is on — not an 8-week SARM blast. forum
- Months at a time in Jake-style talk, cost-limited. forum
- With a GLP: Continuous ATX while the GLP dose is the thing people titrate. forum
- GH + ATX: Nelly’s “real sauce” line — two expensive jobs, not a beginner stack. forum
Timing
- Long-tail talk versus human research: One X post called the half-life about 4 days and used that to explain daily-versus-weekly arguments; that estimate remains unverified here. The checked O304 human paper calls the plasma half-life long and reports steady state after 14 days, but its main text does not supply a numerical human terminal half-life. Steady-state timing alone does not establish a 4-day value or a weekly schedule. forumtrial
- Oral, not a 17-hour DORA: Morning-with-the-stack is the older swallow-timing habit rather than bedtime. One checked oral ATX author used it before fasted cardio but reasoned that timing was unnecessary because of a presumed long half-life; that rationale was not a PK measurement. forum
- Downstream: AMPK/metabolic outcomes are discussed over days to weeks, not as a 90-minute pump. The checked 28-day type 2 diabetes study tracked metabolic endpoints; these are not measurements of a felt window after one gray-market capsule. trialforum
- Phase 2 fatty-liver is the clinic clock; forums are not waiting for that readout. trial
More on what it is
- What it is: An oral research-chem and clinic-pipeline pill. Same molecule as O-304. Amplifier Therapeutics / Cambrian Bio talk. Vendor pages also say OS-01. Not a pin. forum
- Why people talk about it: 2026 X line is “ATX-304 is what everyone wanted MOTS-c to be.” BiohackerJake, Nelly, Tatem, Jay Campbell, Reddit, professionalmuscle. forum
- Vs MOTS-c: MOTS-c is an injectable mitochondrial peptide with a short-pin culture. ATX is a swallow. Same AMPK/mito drawer, different bottle. forum
- Vs metformin / berberine: Same AMPK neighborhood. Forums treat ATX as the expensive pivot “when money permits.” forum
- Not a GLP-1. People stack it *with* sema/tirz/reta in screenshots. forum
- 2026 X line, still loud: Nelly’s Aug 2026 “ATX-304 is what everyone wanted MOTS-c to be” is the screenshot. MOTS-c is the pin people say they “felt nothing” on; ATX is the swallow they say they noticed. Same AMPK drawer, different bottle. forum
- How it works (plain): AMPK is the cell’s energy sensor. The O304 paper describes protection of phosphorylated AMPK from dephosphorylation without inhibiting PP2C phosphatase activity; “blocking the phosphatase” is not its demonstrated mechanism. Mild mitochondrial uncoupling is also discussed. This is not simply metformin’s “make a little energy stress” story. trial
Stacks
- Standalone 100 mg reports: Some public logs describe assessing whether anything changed with ATX alone. This is a reported experiment, not an instruction to begin there. forum
- + Semaglutide / tirz / reta: The 2026 screenshot. Muscle-sparing fat-loss pitch. forum
- + Apitegromab: Tatem’s “light-speed recomp” pile-on. Antibody + AMPK + GLP. forum
- + GH: Nelly. forum
- Vs metformin / berberine, not always with them — AMPK stacking without a clinician is a glucose-drop risk people name. forum
- Vs MOTS-c, not always with it: 2026 X often replaces the pin with the pill. People who stack both call out AMPK overstimulation and overnight glucose. forum
- ATX 100 mg daily with tirz, n=1: Public 2026 log of ATX-304 100 mg with tirz, “no ATX sides,” faster fat-loss claim — one screenshot. anecdote
Access talk
- Two different ATXs: Amplifier / Cambrian trial tablets (not for sale) vs RUO “ATX-304 / O-304 / OS-01” research caps / powder (Elite Research-class shops named on X). forum
- MOTS-c had a July 2026 PCAC compounding fight. ATX is a small-molecule research chem — not that peptide vote. forum
- Identity: OS-01 vs ATX-304 vs O-304 on a bottle is the same-name fight. forum
- Cost is why people stay on metformin. Jake’s “when money permits 150 mg+” line is the access limiter. forum
Labs people mention
- Glucose / CGM is the stack-risk lab — especially + metformin, berberine, MOTS-c, or a GLP. Overnight crash logs are the 2026 watch. forum
- Fasting insulin / “insulin control while abusing calories” is influencer talk, not a panel everyone runs. forum
- Lipids and liver fat are the Phase 1b screenshots people paste (TG, MRI-PDFF) — not a gray-cap protocol. trial
Storage notes
- Capsules or dry powder. Cool, dry. forum
- OS-01 vs ATX-304 vs O-304 on a bottle is the same-name fight — identity is the first check. forum
Watch for
- Not MOTS-c. Different molecule, different milligrams. forum
- Glucose stacking with metformin, berberine, or a GLP. forum
- Uncoupling / heat / “wired” n=1s at the higher swallows. forum
- Cost: The limiter that keeps people on metformin. forum
- Identity: OS-01 / ATX / O-304 labels on gray caps. forum
- Not a clot-busting or thyroid drug. Metabolic experiment only. forum
- Dual AMPK overnight hypo talk when stacked with MOTS-c. anecdote
- Clinic vs bottle: Fatty-liver Phase 2 ≠ a fat-loss supplement. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.